DNLI
Price
$11.77
Change
-$1.02 (-7.97%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
1.71B
38 days until earnings call
RGNX
Price
$6.29
Change
-$0.38 (-5.70%)
Updated
Apr 4 closing price
Capitalization
315.04M
25 days until earnings call
Ad is loading...

DNLI vs RGNX

Header iconDNLI vs RGNX Comparison
Open Charts DNLI vs RGNXBanner chart's image
Denali Therapeutics
Price$11.77
Change-$1.02 (-7.97%)
Volume$17.66K
Capitalization1.71B
REGENXBIO
Price$6.29
Change-$0.38 (-5.70%)
Volume$1.09M
Capitalization315.04M
DNLI vs RGNX Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RGNX commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RGNX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 05, 2025
Stock price -- (DNLI: $12.79 vs. RGNX: $6.67)
Brand notoriety: DNLI and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 123% vs. RGNX: 94%
Market capitalization -- DNLI: $1.71B vs. RGNX: $315.04M
DNLI [@Biotechnology] is valued at $1.71B. RGNX’s [@Biotechnology] market capitalization is $315.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • RGNX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than RGNX.

Price Growth

DNLI (@Biotechnology) experienced а -9.93% price change this week, while RGNX (@Biotechnology) price change was -15.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.73%. For the same industry, the average monthly price growth was -16.65%, and the average quarterly price growth was -18.36%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

RGNX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-10.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.71B) has a higher market cap than RGNX($315M). RGNX YTD gains are higher at: -13.713 vs. DNLI (-37.242). RGNX has higher annual earnings (EBITDA): -198.23M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. RGNX (235M). DNLI has less debt than RGNX: DNLI (48.7M) vs RGNX (82M). RGNX has higher revenues than DNLI: RGNX (83.3M) vs DNLI (0).
DNLIRGNXDNLI / RGNX
Capitalization1.71B315M542%
EBITDA-492.89M-198.23M249%
Gain YTD-37.242-13.713272%
P/E RatioN/AN/A-
Revenue083.3M-
Total Cash832M235M354%
Total Debt48.7M82M59%
FUNDAMENTALS RATINGS
DNLI vs RGNX: Fundamental Ratings
DNLI
RGNX
OUTLOOK RATING
1..100
6969
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8861
P/E GROWTH RATING
1..100
9819
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (76) in the Biotechnology industry is in the same range as DNLI (94). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as RGNX (98). This means that DNLI’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (61) in the Biotechnology industry is in the same range as DNLI (88). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for DNLI (98). This means that RGNX’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 17 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADGIX24.29N/A
N/A
AB Core Opportunities I
SLVCX16.42N/A
N/A
Saratoga Large Capitalization Value C
PRRAX29.09N/A
N/A
Principal Real Estate Securities A
RTSAX36.37N/A
N/A
Russell Inv Tax-Managed US Mid&Sm Cap A
SSBIX12.68N/A
N/A
State Street Balanced Index K